Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Large Growth in Short Interest

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 17,195 shares, a growth of 113.0% from the December 15th total of 8,073 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 42,362 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 42,362 shares, the short-interest ratio is presently 0.4 days. Currently, 1.0% of the company’s shares are short sold.

Catheter Precision Price Performance

NYSEAMERICAN:VTAK traded down $0.03 on Wednesday, hitting $2.02. The stock had a trading volume of 4,953 shares, compared to its average volume of 13,088. The company has a fifty day moving average price of $2.08 and a two-hundred day moving average price of $2.76. Catheter Precision has a 1-year low of $1.49 and a 1-year high of $15.68. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.46 and a current ratio of 0.46.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($26.60) by $24.90. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%.The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $1.20 million. As a group, equities research analysts predict that Catheter Precision will post -8.9 earnings per share for the current year.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.